Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases

What is it about?

Here we describe two patients with metastatic ALK-rearranged NSCLC who had pulmonary disease control with first generation ALK inhibitor. However, disease progressed rapidly in the central nervous system with severe neurological symptoms. Treatment with lorlatinib, a third generation ALK-TKI, led to a rapid radiological and clinical cerebral response in both patients. Therefore lorlatinib can overcome ALK resistance to crizotinib and the presented cases suggest a potential role for lorlatinib in patients with rapidly progressive cerebral and leptomeningeal metastases. 


Featured Image